
ATRC — AtriCure Inc
NASDAQ · Healthcare · Medical Instruments & Supplies
$51.42
+$2.50 (+5.11%)
AtriCure Inc (ATRC) is a medical instruments & supplies company listed on NASDAQ. It is led by Michael H. Carrel, based in 7555 Innovation Way, Mason, OH, United States, 45040, with about 1,350 employees. AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; cryoXT probes, a cryoablation device designed specifically for Cryo Nerve Block therapy; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
Latest reported ATRC revenue for 2025-09-30 was $134.3M. Net income was -$267.0K. Revenue was down 1.4% from 2025-06-30 to 2025-09-30. ATRC currently screens at market cap $1.37B.
Use this ATRC page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ATRC quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ATRC SEC filings page. Lician reads the product cache first so this HTML stays unique to AtriCure Inc even when a live quote feed is slow.
About AtriCure Inc
AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; cryoXT probes, a cryoablation device designed specifically for Cryo Nerve Block therapy; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
ATRC Key Statistics
Market Cap
$1.37B
Volume
859,640
Previous Close
$48.68
Day Range
$47.06 – $48.55
EPS
-$0.95
Revenue
$465.31M
Net Income
-$44.70M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+16.5%
Profit Margin
-9.6%
Employees
1,350
ATRC Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $465.31M | $399.25M | $330.38M | $274.33M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$44.70M | -$30.44M | -$46.47M | $50.20M |
| EPS (Diluted) | -$0.95 | -$0.66 | -$1.02 | $1.09 |
Total Assets
$609.33M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$122.72M
Operating Cash Flow
$12.20M
Free Cash Flow
$0.00
AtriCure Inc Company Information
- CEO, President & Director
- Michael H. Carrel
- Headquarters
- 7555 Innovation Way, Mason, OH, United States, 45040
- Website
- www.atricure.com
- Phone
- 513 755 4100
- IPO / Founded
- 2005-08-05
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies